发布求助
文献互助 智能选刊 最新文献

Clinical Lymphoma, Myeloma & Leukemia最新文献

筛选
英文 中文
P-014 Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial P-014 ABBV-383（一种BCMA双特异性抗体）对复发性/难治性多发性骨髓瘤黑人患者的疗效和安全性：一期试验的亚组分析
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01917-7
{"title":"P-014 Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial","authors":"","doi":"10.1016/S2152-2650(24)01917-7","DOIUrl":"10.1016/S2152-2650(24)01917-7","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-42 Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in Patients With Plasma Cell Premalignancy Unveils Co-Regulation of Disease Progression by Tumor Biology and Immune Dysregulation 对浆细胞癌前病变患者的 600 万个肿瘤细胞和免疫细胞进行 OA-42 单细胞 RNA 测序，揭示肿瘤生物学和免疫失调对疾病进展的共同调控作用
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01883-4
{"title":"OA-42 Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in Patients With Plasma Cell Premalignancy Unveils Co-Regulation of Disease Progression by Tumor Biology and Immune Dysregulation","authors":"","doi":"10.1016/S2152-2650(24)01883-4","DOIUrl":"10.1016/S2152-2650(24)01883-4","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-45 Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA Study OA-45皮下注射达拉土单抗加来那度胺与单用来那度胺作为移植后新诊断多发性骨髓瘤的维持疗法：AURIGA 3 期研究的初步结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01886-X
{"title":"OA-45 Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA Study","authors":"","doi":"10.1016/S2152-2650(24)01886-X","DOIUrl":"10.1016/S2152-2650(24)01886-X","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-17 Liquid Chromatography Mass Spectrometry (LC-MS) for Identification of Exceptional Responders in Newly Diagnosed Multiple Myeloma (NDMM) OA-17 用液相色谱质谱法（LC-MS）鉴定新诊断多发性骨髓瘤（NDMM）中的特殊反应者
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01858-5
{"title":"OA-17 Liquid Chromatography Mass Spectrometry (LC-MS) for Identification of Exceptional Responders in Newly Diagnosed Multiple Myeloma (NDMM)","authors":"","doi":"10.1016/S2152-2650(24)01858-5","DOIUrl":"10.1016/S2152-2650(24)01858-5","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-51 Efficacy of Dara-RVD Induction Therapy in Newly Diagnosed Myeloma (NDMM) Patients ≥65 Years of Age OA-51 Dara-RVD 诱导疗法对年龄≥65 岁的新诊断骨髓瘤 (NDMM) 患者的疗效
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01892-5
{"title":"OA-51 Efficacy of Dara-RVD Induction Therapy in Newly Diagnosed Myeloma (NDMM) Patients ≥65 Years of Age","authors":"","doi":"10.1016/S2152-2650(24)01892-5","DOIUrl":"10.1016/S2152-2650(24)01892-5","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-14 Prospective Functional Bone Disease Evaluation of Newly Diagnosed Multiple Myeloma with Combined Use of (18)F-FDG-PET/CT and Whole-Body Diffusion Weighted Magnetic Resonance OA-14 联合使用(18)F-FDG-PET/CT和全身弥散加权磁共振对新诊断的多发性骨髓瘤进行前瞻性骨病功能评估
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01855-X
{"title":"OA-14 Prospective Functional Bone Disease Evaluation of Newly Diagnosed Multiple Myeloma with Combined Use of (18)F-FDG-PET/CT and Whole-Body Diffusion Weighted Magnetic Resonance","authors":"","doi":"10.1016/S2152-2650(24)01855-X","DOIUrl":"10.1016/S2152-2650(24)01855-X","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-007 Absolute Lymphocyte Count at Day 30 (Not Earlier) and Early CRS Predict Delayed Responses to Teclistamab: Results From the US Myeloma Immunotherapy Consortium P-007 第30天（而非更早）的绝对淋巴细胞计数和早期CRS可预测对替卡单抗的延迟反应：美国骨髓瘤免疫疗法联盟的研究结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01910-4
{"title":"P-007 Absolute Lymphocyte Count at Day 30 (Not Earlier) and Early CRS Predict Delayed Responses to Teclistamab: Results From the US Myeloma Immunotherapy Consortium","authors":"","doi":"10.1016/S2152-2650(24)01910-4","DOIUrl":"10.1016/S2152-2650(24)01910-4","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-52 Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study OA-52伊沙妥昔单抗加来那度胺和地塞米松与硼替佐米与伊沙妥昔单抗加来那度胺和地塞米松治疗新诊断的不符合移植条件的多发性骨髓瘤：获益研究
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01893-7
{"title":"OA-52 Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study","authors":"","doi":"10.1016/S2152-2650(24)01893-7","DOIUrl":"10.1016/S2152-2650(24)01893-7","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-020 Treatment Positioning Model to Evaluate the Survival Benefit of Ciltacabtagene Autoleucel in Second-Line Compared With Later-Line Treatment of Lenalidomide-Refractory Multiple Myeloma P-020 用治疗定位模型评估来那度胺难治性多发性骨髓瘤二线治疗与后线治疗中西他卡巴他昔单抗的生存获益
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01923-2
{"title":"P-020 Treatment Positioning Model to Evaluate the Survival Benefit of Ciltacabtagene Autoleucel in Second-Line Compared With Later-Line Treatment of Lenalidomide-Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01923-2","DOIUrl":"10.1016/S2152-2650(24)01923-2","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-033 External Control Analysis for KarMMa-3: Idecabtagene Vicleucel (ide-cel) vs Real-World Standard of Care (RW SoC; Connect MM) for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) P-033 KarMMa-3 的外部对照分析：Idecabtagene Vicleucel（ide-cel）与真实世界标准护理（RW SoC；Connect MM）对比，用于治疗暴露于三类药物的复发性/难治性多发性骨髓瘤（RRMM
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01936-0
{"title":"P-033 External Control Analysis for KarMMa-3: Idecabtagene Vicleucel (ide-cel) vs Real-World Standard of Care (RW SoC; Connect MM) for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)","authors":"","doi":"10.1016/S2152-2650(24)01936-0","DOIUrl":"10.1016/S2152-2650(24)01936-0","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信